semaglutide obesity phase 3 Trial of in Metabolic Dysfunction–Associated Steatohepatitis once-weekly semaglutide in adults with

doi: 10.1021/acs.chemrev.1c00024

Tesamorelin Tesamorelin is an FDAapproved peptide for reducing visceral fat, particularly in HIVassociated lipodystrophy, and has robust clinical evidence behind it: Tesamorelin stimulates growth hormone release more effectively than AOD9604

Current approved treatment options for glaucoma include eyedrops, oral medications, laser surgery, or microsurgery

But they're not exactly the same thing

The decision to discontinue semaglutide should be made through shared decision-making with your healthcare provider who can assess your individual circumstances and develop an appropriate plan